Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-23T22:59:33.043Z Has data issue: false hasContentIssue false

Chapter 9 - Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)

from Part 2 - Psychopharmacology of the Main Psychotropic Drug Groups

Published online by Cambridge University Press:  29 May 2020

By
Robert McCutcheon ,
Stephen J. Kaar  and
Oliver D. Howes
Edited by
Peter M. Haddad  and
David J. Nutt
Peter M. Haddad
Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt
Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access

Summary

This chapter provides a wide-ranging review of the clinical pharmacology of drugs for the treatment of schizophrenia and psychosis other than clozapine. These are dopamine receptor antagonists and dopamine partial agonists (as per the new Neuroscience-based Nomenclature (NbN) classification). This chapter covers their pharmacodynamics, pharmacokinetics, adverse effects, the latest evidence regarding their ‘antipsychotic’ mechanism of action, their use in the acute and maintenance treatment of schizophrenia, other therapeutic indications and some controversies that surround their use.Dopamine receptor antagonists and dopamine partial agonists are commonly referred to as antipsychotics. As a clinical shorthand the term ‘antipsychotic’ is likely to remain in use.

Type
Chapter
Information
Seminars in Clinical Psychopharmacology , pp. 290 - 325
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adams, CE, Fenton, MK, Quraishi, S, David, AS (2001). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry, 179, 290–299.Google Scholar
Arranz, MJ, Rivera, M, Munro, JC (2011). Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs, 25(11), 933–939.Google Scholar
Ashok, AH, Marques, TR, Jauhar, S, et al. (2017). The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry, 22(5), 666–679.Google Scholar
Bagnall, AM, Jones, L, Ginnelly, L, et al. (2003). A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess, 7(13), 1–193.Google Scholar
Beck, K, McCutcheon, R, Bloomfield, MAP, et al. (2014). The practical management of refractory schizophrenia – the Maudsley Treatment Review and Assessment Team service approach. Acta Psychiatr Scand, 130(6), 427–438.Google Scholar
Beresford, R, Ward, A (1987). Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs, 33(1), 31–49.Google Scholar
Bleakley, S (2012). Identifying and reducing the risk of antipsychotic drug interactions. Prog Neurol Psychiatry, 16(2), 20–24.Google Scholar
Bolden, C, Cusack, B, Richelson, E (1992). Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther, 260(2), 576–580.Google Scholar
Brugger, SP, Howes, OD (2017). Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis. JAMA Psychiatry, 74(11), 1104–1111.CrossRefGoogle ScholarPubMed
Buckley, PF, Schooler, NR, Goff, DC, et al. (2016). Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study. Psychiatr Serv, 67(12), 1370–1372.CrossRefGoogle Scholar
Bymaster, FP, Calligaro, DO, Falcone, JF, et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87–96.Google Scholar
Carbon, M, Kane, MJ, Leucht, S, Correll, CU (2018). Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry, 17(3), 330–340. doi:10.1002/wps.20579.Google Scholar
Carlsson, A, Lindqvist, M (1963). Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh), 20(2), 140–144.CrossRefGoogle ScholarPubMed
Cipriani, A, Barbui, C, Salanti, G, et al. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet, 378(9799), 1306–1315.CrossRefGoogle Scholar
Correll, CU (2010). From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry, 25(Suppl 2), S12–S21. doi:10.1016/S0924-9338(10)71701-6.Google Scholar
Correll, CU, Citrome, L, Haddad, PM, et al. (2016). The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry, 77(Suppl 3), 1–24.CrossRefGoogle ScholarPubMed
Creese, I, Burt, D, Snyder, S (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192(4238), 481–483.CrossRefGoogle ScholarPubMed
Davidson, M, Saoud, J, Staner, C, et al. (2017). Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry, 174(12), 1195–1202.Google Scholar
Davies, DL, Shepherd, M (1955). Reserpine in the treatment of anxious and depressed patients. Lancet, 269(6881), 117–120.CrossRefGoogle ScholarPubMed
Dold, M, Aigner, M, Lanzenberger, R, Kasper, S (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol, 18(9), pyv047.CrossRefGoogle ScholarPubMed
Douglas, IJ, Smeeth, L (2008). Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ, 337, a1227.Google Scholar
Dzahini, O, Singh, N, Taylor, D, Haddad, PM (2018). Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol, 32(11), 1167–1181.Google Scholar
Emsley, R, Medori, R, Koen, L, et al. (2008). Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol, 28(2), 210–213.Google Scholar
Fallon, P, Dursun, S, Deakin, B (2012). Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol, 2(1), 13–22.CrossRefGoogle ScholarPubMed
Frampton, JE (2010). Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs, 70(17), 2289–2313.CrossRefGoogle ScholarPubMed
González-Blanco, L, Greenhalgh, AMD, Garcia-Rizo, C, et al. (2016). Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: a meta-analysis. Schizophr Res, 174(1), 156–160.Google Scholar
Goodwin, GM, Haddad, PM, Ferrier, IN, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 30(6), 495–553.Google Scholar
Grace, AA, Gomes, FV (2019). The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention. Schizophr Bull, 45(1), 148–157. doi:10.1093/schbul/sbx199.Google Scholar
Graff-Guerrero, A, Mizrahi, R, Agid, O, et al. (2009). The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology, 34(4), 1078–1086.Google Scholar
Graff-Guerrero, A, Mamo, D, Shammi, C, et al. (2013). The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11c]-(+)-PHNO. Arch Gen Psychiatry, 66(6), 606–615.Google Scholar
Grossman, I, Sullivan, PF, Walley, N, et al. (2008). Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med, 10(10), 720–729.Google Scholar
Haddad, PM, Anderson, IM (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62(11), 1649–1671.Google Scholar
Haddad, PM, Correll, CU (2018). The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol, 8(11), 303–318.Google Scholar
Haddad, PM, Wieck, A (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs, 64, 2291–2314.Google Scholar
Hedges, D, Jeppson, K, Whitehead, P (2003). Antipsychotic medication and seizures: a review. Drugs Today (Barc), 39(7), 551–557.Google Scholar
Heres, S, Hamann, J, Kissling, W, Leucht, S (2006). Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry, 67(12), 1948–1953.Google Scholar
Hirsch, SR, Gaind, R, Rohde, PD, Stevens, BC, Wing, JK (1973). Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo. Br Med J, 1(5854), 633–637.CrossRefGoogle ScholarPubMed
Ho, BC, Andreasen, NC, Ziebell, S, Pierson, R, Magnotta, V (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry, 68(2), 128–137.Google Scholar
Horvitz-Lennon, M, Mattke, S, Predmore, Z, Howes, OD (2017). The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry, 174(5), 421–426.Google Scholar
Howes, OD, Kapur, S (2014). A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type b (normodopaminergic). Br J Psychiatry, 205, 1–3.Google Scholar
Howes, OD, McCutcheon, R. (2017). Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry, 7(2), e1024. doi:10.1038/tp.2016.278.Google Scholar
Howes, OD, Kambeitz, J, Kim, E, et al. (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry, 69(8), 776–786.Google Scholar
Howes, O, McCutcheon, R, Stone, J (2015). Glutamate and dopamine in schizophrenia: an update for the 21(st) century. J Psychopharmacol, 29(2), 97–115.CrossRefGoogle Scholar
Howes, OD, McCutcheon, R, Agid, O, et al. (2017a). Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry, 174(3), 216–229.Google Scholar
Howes, OD, McCutcheon, R, Owen, MJ, Murray, RM (2017b). The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry, 81(1), 9–20.Google Scholar
Jauhar, S, Veronese, M, Rogdaki, M, et al. (2017). Regulation of dopaminergic function: an [18 F]-DOPA PET apomorphine challenge study in humans. Transl Psychiatry, 7(2), e1027. doi:10.1038/tp.2016.270.CrossRefGoogle ScholarPubMed
Johnsen, E, Kroken, RA, Abaza, M, Olberg, H, Jørgensen, HA (2008). Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol, 28(6), 686–690. doi:10.1097/JCP.0b013e31818ba5d8.Google Scholar
Johnson, DAW (2009). Historical perspective on antipsychotic long-acting injections. Br J Psychiatry, 195(52), S7–S12.Google Scholar
Kane, JM, Detke, HC, Naber, D, et al. (2010). Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry, 167(2), 181–189.Google Scholar
Kapur, S (1998). A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry, 3(2), 135–140.Google Scholar
Kapur, S, Seeman, P (2000). Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci, 25(2), 161–166.Google Scholar
Kapur, S, Seeman, P (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry, 158(3), 360–369.Google Scholar
Kapur, S, Zipursky, RB, Remington, G, et al. (1998). 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry, 155(7), 921–928.Google Scholar
Kapur, S, Zipursky, RB, Remington, G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry, 156(2), 286–293.Google Scholar
Kapur, S, Zipursky, R, Jones, C, Remington, G, Houle, S (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry, 157(4), 514–520.CrossRefGoogle ScholarPubMed
Kebabian, JW, Calne, DB (1979). Multiple receptors for dopamine. Nature, 277(5692), 93–96.CrossRefGoogle ScholarPubMed
Kim, B, Lee, SH, Choi, TK, et al. (2008). Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry, 32(5), 1231–1235. doi:10.1016/j.pnpbp.2008.03.012.Google Scholar
King, C, Voruganti, LNP (2002). What’s in a name? The evolution of the nomenclature of antipsychotic drugs. J Psychiatry Neurosci, 27(3), 168–175.Google Scholar
Kirson, NY, Weiden, PJ, Yermakov, S, et al. (2013). Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry, 74(6), 568–575.Google Scholar
Kisely, S, Sawyer, E, Robinson, G, Siskind, D (2015). A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome. Schizophr Res, 166(1–3), 178–186.Google Scholar
Kishimoto, T, Robenzadeh, A, Leucht, C, et al. (2014). Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull, 40(1), 192–213.CrossRefGoogle ScholarPubMed
Kwentus, J, Riesenberg, RA, Marandi, M, et al. (2012). Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord, 14(1), 31–40. doi:10.1111/j.1399-5618.2011.00975.x.Google Scholar
Laborit, H, Huguenard, P, Alluaume, R (1952). Un noveau stabilisateur végétatif (le 4560 RP). La Presse Médicale, 60, 206–208.Google Scholar
Lambert, M, Conus, P, Eide, P, et al. (2004). Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry, 19(7), 415–422.Google Scholar
Lesem, MD, Tran-Johnson, TK, Riesenberg, RA, et al. (2011). Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry, 198(1), 51–58. doi:10.1192/bjp.bp.110.081513.Google Scholar
Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res, 35(1), 51–68.Google Scholar
Leucht, S, Busch, R, Kissling, W, Kane, JM (2007). Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry, 68(3), 352–360.Google Scholar
Leucht, S, Corves, C, Arbter, D, et al. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373(9657), 31–41.Google Scholar
Leucht, S, Hierl, S, Kissling, W, Dold, M, Davis, JM (2012a). Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry, 200(2), 97–106.Google Scholar
Leucht, S, Tardy, M, Komossa, K, et al. (2012b). Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev, (5), CD008016.Google Scholar
Leucht, S, Cipriani, A, Spineli, L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382(9896), 951–962.Google Scholar
Leucht, S, Leucht, C, Huhn, M, et al. (2017). Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry, 174(10), 927–942.Google Scholar
Lieberman, JA, 3rd (2004). Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry, 6(Suppl 2), 20–23.Google Scholar
Lindström, L, Lindström, E, Nilsson, M, Höistad, M (2017). Maintenance therapy with second generation antipsychotics for bipolar disorder – a systematic review and meta-analysis. J Affect Disord, 213, 138–150. doi:10.1016/j.jad.2017.02.012.Google Scholar
Mallikaarjun, S, Kane, JM, Bricmont, P, et al. (2013). Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res, 150(1), 281–288.Google Scholar
Maneeton, N, Maneeton, B, Woottiluk, P, et al. (2016). Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther, 10, 259–276. doi:10.2147/DDDT.S89485.Google Scholar
Marder, SR, Hubbard, JW, Van Putten, T, Midha, KK (1989). Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology, 98(4), 433–439.Google Scholar
Mauri, MC, Volonteri, LS, Colasanti, A, et al. (2007). Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet, 46(5), 359–388.Google Scholar
McCutcheon, R, Beck, K, Bloomfield, MA, et al. (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol, 29(8), 892–897.CrossRefGoogle ScholarPubMed
McCutcheon, R, Beck, K, D’Ambrosio, E, et al. (2017). Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand, 137(1), 39–46.Google Scholar
McCutcheon, R, Beck, K, Jauhar, S, Howes, OD (2018). Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull, 44(6), 1301–1311.Google Scholar
McCutcheon, RA, Abi-Dargham, A, Howes, OD (2019). Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci, 42(3), 205–220.Google Scholar
Meltzer, HY, Matsubara, S, Lee, J-C (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine. J Pharmacol Exp Ther, 251(1), 238–246.Google Scholar
Minzenberg, MJ, Poole, JH, Benton, C, Vinogradov, S (2004). Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry, 161(1), 116–124.Google Scholar
Murphy, BP, Chung, Y-C, Park, T-W, McGorry, PD (2006). Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res, 88(1–3), 5–25.Google Scholar
Murray, RM, Quattrone, D, Natesan, S, et al. (2016). Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry, 209(5), 361–365.CrossRefGoogle ScholarPubMed
Nyberg, S, Farde, L, Eriksson, L, Halldin, C, Eriksson, B (1993). 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology, 110(3), 265–272.Google Scholar
Oehl, M, Hummer, M, Fleischhacker, WW (2000). Compliance with antipsychotic treatment. Acta Psychiatr Scand, 102, 83–86.Google Scholar
Olianas, MC, Maullu, C, Onali, P (1997). Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol, 122(3), 401–408.Google Scholar
Ortiz-Orendain, J, Castiello-de Obeso, S, Colunga-Lozano, LE, et al. (2017). Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev, (6), CD009005. doi:10.1002/14651858.CD009005.pub2.Google Scholar
Pantelis, C, Velakoulis, D, McGorry, PD, et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 361(9354), 281–288.Google Scholar
Park, EJ, Amatya, S, Kim, MS, et al. (2013). Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res, 36(6), 651–659.Google Scholar
Parsons, B, Allison, DB, Loebel, A, et al. (2009). Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res, 110(1–3), 103–110.Google Scholar
Pelonero, AL, Levenson, JL, Pandurangi, AK (1998). Neuroleptic malignant syndrome: a review. Psychiatr Serv, 49(9), 1163–1172.Google Scholar
Perreault, ML, Hasbi, A, Alijaniaram, M, et al. (2010). The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem, 285(47), 36625–36634.Google Scholar
Ravyn, D, Ravyn, V, Lowney, R, Nasrallah, HA (2013). CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res, 149(1–3), 1–14.Google Scholar
Ronaldson, KJ (2017). Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS Drugs, 31(9), 777–795.Google Scholar
Rummel-Kluge, C, Komossa, K, Schwarz, S, et al. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res, 123(2–3), 225–233.Google Scholar
Sachs, GS, Nierenberg, AA, Calabrese, JR, et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med, 356, 1711–1722. doi:10.1056/NEJMoa064135.Google Scholar
Samara, MT, Dold, M, Gianatsi, M, et al. (2016). Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry, 73(3), 199–210.Google Scholar
Seeman, P (2001). Antipsychotic drugs, dopamine receptors, and schizophrenia. Clin Neurosci Res, 1(1–2), 53–60.Google Scholar
Seeman, P (2011). All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci Ther, 17(2), 118–132.Google Scholar
Seeman, P (2012). Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. Synapse, 66(1), 88–93.Google Scholar
Seeman, P, Chau-Wong, M, Tedesco, J, Wong, K (1975). Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A, 72(11), 4376–4380.Google Scholar
Sepede, G, De Berardis, D, Gambi, F, et al. (2006). Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol, 26(1), 45–49.Google Scholar
Shen, WW (1999). A history of antipsychotic drug development. Compr Psychiatry, 40, 407–414.Google Scholar
Siskind, D, McCartney, L, Goldschlager, R, Kisely, S (2016). Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry, 209(5), 385–392.Google Scholar
Slifstein, M, van de Giessen, E, Van Snellenberg, J, et al. (2015). Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry, 72(4), 316–324.Google Scholar
Soderberg, MM, Dahl, ML (2013). Pharmacogenetics of olanzapine metabolism. Pharmacogenomics, 14(11), 1319–1336.Google Scholar
Soldin, OP, Mattison, DR (2009). Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet, 48(3), 143–157.Google Scholar
Spielmans, GI, Berman, MI, Linardatos, E, et al. (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med, 10(3), e1001403.Google Scholar
Spina, E, de Leon, J (2007). Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol, 100(1), 4–22.Google Scholar
Stein, G, Wilkinson, G (eds.) (2007). Seminars in General Adult Psychiatry, 2nd ed. London: Royal College of Psychiatrists.Google Scholar
Taylor, D (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry, 195(52), S13–S19.Google Scholar
Tiihonen, J, Haukka, J, Taylor, M, et al. (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry, 168(6), 603–609.Google Scholar
Tiihonen, J, Mittendorfer-Rutz, E, Majak, M, et al. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry, 74(7), 686–693.Google Scholar
Veijola, J, Guo, JY, Moilanen, JS, et al. (2014). Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS One, 9(7), e101689.Google Scholar
Weiden, PJ, Schooler, NR, Weedon, JC, et al. (2009). A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry, 70(10), 1397–1406. doi:10.4088/JCP.09m05284yel.Google Scholar
Weinberger, DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry, 44(7), 660–669.Google Scholar
Wijkstra, J, Lijmer, J, Burger, H, et al. (2015). Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev, (7), CD004044.Google Scholar
Wu, CS, Wang, SC, Yeh, IJ, Liu, SK (2016). Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. J Clin Psychiatry, 77(5), e573–e579.Google Scholar
Young, SL, Taylor, M, Lawrie, SM (2015). ‘First do no harm.’ A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol, 29(4), 353–362.Google Scholar
Zeng, XP, Le, F, Richelson, E (1997). Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol, 321(3), 349–354.Google Scholar
Zhang, ZJ, Yao, ZJ, Liu, W, Fang, Q, Reynolds, GP (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry, 184, 58–62.Google Scholar
Zhu, Y, Li, C, Huhn, M, et al. (2017). How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol, 27(9), 835–844. doi:10.1016/j.euroneuro.2017.06.011.Google Scholar
Zohar, J, Stahl, S, Moller, H-J, et al. (2015). A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol, 25(12), 2318–2325.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×